213 related articles for article (PubMed ID: 18577511)
1. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.
Dicker IB; Terry B; Lin Z; Li Z; Bollini S; Samanta HK; Gali V; Walker MA; Krystal MR
J Biol Chem; 2008 Aug; 283(35):23599-609. PubMed ID: 18577511
[TBL] [Abstract][Full Text] [Related]
2. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
[TBL] [Abstract][Full Text] [Related]
3. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
4. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
[TBL] [Abstract][Full Text] [Related]
5. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
Zahm JA; Bera S; Pandey KK; Vora A; Stillmock K; Hazuda D; Grandgenett DP
Antimicrob Agents Chemother; 2008 Sep; 52(9):3358-68. PubMed ID: 18591263
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
8. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
9. Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: design and characterization of the enzymatic properties.
Shadrina O; Krotova O; Agapkina J; Knyazhanskaya E; Korolev S; Starodubova E; Viklund A; Lukashov V; Magnani M; Medstrand P; Karpov V; Gottikh M; Isaguliants M
Biochimie; 2014 Jul; 102():92-101. PubMed ID: 24594066
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
11. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
12. Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
Peese KM; Naidu BN; Patel M; Li C; Langley DR; Terry B; Protack T; Gali V; Lin Z; Samanta HK; Zheng M; Jenkins S; Dicker IB; Krystal MR; Meanwell NA; Walker MA
Bioorg Med Chem Lett; 2020 Feb; 30(3):126784. PubMed ID: 31761656
[TBL] [Abstract][Full Text] [Related]
13. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action.
Tsiang M; Jones GS; Niedziela-Majka A; Kan E; Lansdon EB; Huang W; Hung M; Samuel D; Novikov N; Xu Y; Mitchell M; Guo H; Babaoglu K; Liu X; Geleziunas R; Sakowicz R
J Biol Chem; 2012 Jun; 287(25):21189-203. PubMed ID: 22535962
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.
Depatureaux A; Quashie PK; Mesplède T; Han Y; Koubi H; Plantier JC; Oliveira M; Moisi D; Brenner B; Wainberg MA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7141-50. PubMed ID: 25224008
[TBL] [Abstract][Full Text] [Related]
15. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
[TBL] [Abstract][Full Text] [Related]
16. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.
Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA
Antimicrob Agents Chemother; 2015 Jan; 59(1):310-6. PubMed ID: 25348535
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
[TBL] [Abstract][Full Text] [Related]
18. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
19. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
20. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
